Yesterday, RBC Capital lowered the firm's price target on Clarivate to $3 from $5 and keeps a Sector Perform rating on the shares. The company delivered solid free cash flow growth and guided to about 10% free cash flow growth at the midpoint in FY26, though the firm's price target reflects the concerns around ongoing AI disintermediation risk, and execution around a potential Life Sciences and Healthcare segment sale, the analyst tells investors in a research note.
